CVS Health Corp vs PepsiCo, Inc. — how do they compare? CVS Health Corp trades at $88.26 (market cap $112.29B), while PepsiCo, Inc. trades at $127.74 (market cap $174.89B). The key difference: PepsiCo, Inc. is the larger of the two by market cap, and PepsiCo, Inc. pays the higher dividend (4.61%). Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and PepsiCo, Inc. for 107 Days on average.
| CVS | PEP | |
|---|---|---|
Market Cap | $112.29B | $174.89B |
Volume | 7,763,676 | 23,968,864 |
Sector | Health | Consumer Staples |
52-Week High | $110.60 | $170.44 |
52-Week Low | $70.08 | $123.64 |
Typical Hold Time | 83 Days | 107 Days |
Enterprise Value | $174.64B | $215.61B |
Dividend Yield | 3.03% | 4.61% |
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.95, up 1.76% on the day, with a bullish technical signal and strong analyst support. Recent earnings beats in Q1 and Q2 2026, alongside steady revenue growth to $402.07B in 2025, highlight operational strength. The stock's valuation appears attractive with a P/E of 23.17 and P/S of 0.27, while a consensus price target of $111.20 suggests significant upside potential. Positive news includes Aetna's 2027 Medicare plan enhancements and a declared quarterly dividend.
The outlook for CVS remains positive, driven by earnings momentum and strategic initiatives in healthcare services. Key risks include reimbursement pressures and regulatory scrutiny, but Wall Street's 85% buy rating and institutional interest underscore confidence. Investors should weigh the stock's growth prospects against margin volatility and debt levels, with the current price offering a favorable entry point relative to targets.
PepsiCo (PEP) trades at $123.64, down 1.65% on the day, with a bearish technical signal despite strong fundamental performance. The company has consistently beaten earnings estimates for four consecutive quarters, with Q3 2026 EPS of $2.34 exceeding expectations. Revenue growth remains steady at $93.93B for 2025, though net income margin declined to 8.77%. Recent news highlights price adjustments for snack products and sponsorship changes.
PepsiCo presents a mixed investment case with strong profitability metrics (ROE 51.59%) and analyst consensus price target of $146.77 (18.7% upside), but faces headwinds from consumer price sensitivity and technical weakness. The company's cash flow stability and dividend payments provide defensive characteristics, though execution risks in North American markets warrant monitoring.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →